comprehensive -WSS

comprehensive

author：focus 2025-09-29 01:08:27 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： High breast density mammograms need follow

WSS

In medicine, common shorthands can shortchange care

Dog Aging Project founders on what lies ahead after losing funding

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

The UK government moves asylum

HPV vaccine, cervical cancer study delivers historic results

focus

comprehensive

Wikipedia

Cancer drug shortages should be causing more outrage

Medicare drug price lawsuits could be good politics for Biden

Supreme Court strikes down use of affirmative action

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HPV vaccine, cervical cancer study delivers historic results

Novavax promises a turnaround & Lilly roils the obesity market

Microsoft launches AI tool for clinical documentation through Epic

Wildfire smoke exposes gaps in outdoor worker protections

Cardiologists urge adding sexual orientation, gender identity to health records

explore

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Inaction leaves children at risk from dangerous chemotherapy drug

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

At least 12 people were injured in a blast at a port in northwest Turkey

Maisha Meds is a PBM, but don't call it that

There's an unseen cost to disruptive road

entertainment

entertainment

hotspot

Wikipedia